Showing results (111-120 of 299) with videos related to
Sort By:
Pageof 30
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 23, 2009
Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in CaliforniaEllen T Chang, Sarah J Shema, Heather A Wakelee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradoxManali I Patel, Clayton W Schupp, Scarlett L Gomez, et al.Clinical Chemistry|January 4, 2021
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response MonitoringJared C Nesvet, Katie A Antilla, Danielle S Pancirer, et al.Anti-Cancer Drugs|April 5, 2013
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief reportSukhmani K Padda, Laveena Chhatwani, Lisa Zhou, et al.Journal of Oncology Practice|October 2, 2014
Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?Manali I Patel, Donna C Williams, Carla Wohlforth, et al.Circulation|June 28, 2022
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced MyocarditisHan Zhu, Francisco X Galdos, Daniel Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2018
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung CancerNathan A Pennell, Joel W Neal, Jamie E Chaft, et al.JTO Clinical and Research Reports|December 3, 2024
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLCJacqueline V Aredo, Heather A Wakelee, Kavitha J Ramchandran, et al.Nature Reviews. Clinical Oncology|July 1, 2026
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancerYago Garitaonaindia, Heather A Wakelee, Martin Reck, et al.JTO Clinical and Research Reports|May 31, 2022
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional ExperienceA J Piper-Vallillo, Julia K Rotow, Jacqueline V Aredo, et al.Pageof 30